ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Rheumatoid Factor"

  • Abstract Number: 1654 • ACR Convergence 2021

    Comparative Characteristics of the Natural Course of Early Rheumatoid Arthritis with Onset at a Young Age (18-49 Years) and Older (50 Years and Older) Patients Who Did Not Take DMARDs, Biologics, Other Targeted Drugs, Corticoids According to the Russian Register of Arthritis OREL

    Azamat Satybaldyev, Galina Gridneva, Anna Misiyuk, Natalia Demidova, Kamalia Kasumova and Evgeny Nasonov, V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Comparison of frequency of different clinical features of the natural course at the stage of early rheumatoid arthritis (RA) in patients with young and…
  • Abstract Number: 0007 • ACR Convergence 2021

    Divergent Reactivities of Rheumatoid Factors and Anti-Modified Protein Antibodies Converge on IgG Epitopes

    Aisha Mergaert1, Zihao Zheng1, Michael Denny1, Maya Amjadi1, Janna Bashar1, Michael Newton1, Vivianne Malmström2, Caroline Grönwall2, Sara McCoy1 and Miriam Shelef1, 1University of Wisconsin, Madison, WI, 2Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) patients often develop rheumatoid factors (RFs), antibodies that bind IgG Fc, and anti-modified protein antibodies (AMPAs), multi-reactive autoantibodies that commonly bind…
  • Abstract Number: 0015 • ACR Convergence 2021

    Rheumatoid Factor Recognizes Specific Domains of IgG Heavy Chain Complexed with HLA Class II Molecules

    Shanshan Zhang1, Hideaki Tsuji1, Hui Jin2, Koji Kitagori1, Shuji Akizuki3, Kosaku Murakami1, Ran Nakashima1, Hajime Yoshifuji1, Masao Tanaka1, Hisashi Arase2, Koichiro Ohmura4 and Akio Morinobu1, 1Kyoto University, Kyoto, Japan, 2Osaka University, Osaka, Japan, 3Kyoto Universtiy, Kyoto City, Japan, 4Kobe City Medical Center General Hospital, Kobe, Japan

    Background/Purpose: Rheumatoid factor (RF) is an autoantibody that binds to IgG Fc region (CH2 and CH3 domains) and is detectable in patients with rheumatoid arthritis…
  • Abstract Number: 0039 • ACR Convergence 2021

    Elevated IgA Subclass Levels in Rheumatoid Arthritis Patients: Indications of a Mucosal Origin?

    Veerle Derksen, Cornelia F. Allaart, Annette H.M van der Helm-van Mil, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Mucosal surfaces may be involved in the pathophysiology of rheumatoid arthritis (RA) (1). IgA is the most abundant class of immunoglobulin at mucosal sites…
  • Abstract Number: 0253 • ACR Convergence 2021

    Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort

    Nayimisha Balmuri1, William Soulsby2, Victoria Cooley3, Linda Gerber4, Erica Lawson2 and Karen Onel1, 1Hospital for Special Surgery, New York, NY, 2University of California San Francisco, San Francisco, CA, 3Weil Cornell Medicine, New York, NY, 4Weill Cornell Medicine, New York, NY

    Background/Purpose: Children with rheumatoid factor (RF) positive polyarticular JIA (pJIA) are less likely to go into remission and more likely to develop erosive disease than…
  • Abstract Number: 0269 • ACR Convergence 2021

    Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis

    Tate Johnson1, Michael Duryee2, Carlos Hunter2, Punyasha Roul2, Yangyuna Yang2, Jeremy Sokolove3, William Robinson4, Joshua Baker5, Geoffrey Thiele2, Ted Mikuls2 and Bryant England2, 1University of Nebraska Medical Center, Elkhorn, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Stanford University School of Medicine, Berwyn, PA, 4Stanford University, Stanford, CA, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
  • Abstract Number: 0273 • ACR Convergence 2021

    Abnormalities in Left Ventricular Geometry Influenced by Higher Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Titers in Rheumatoid Arthritis Patients

    Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico

    Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing left ventricular (LV) geometry abnormalities which can result in cardiac death. High titers of…
  • Abstract Number: 0440 • ACR Convergence 2021

    Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events

    Kristen Mathias1, Marco Lopez Velazquez1 and Pankti Reid2, 1University of Chicago, Chicago, IL, 2University of Chicago Medical Center, Chicago, IL

    Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
  • Abstract Number: 0463 • ACR Convergence 2021

    Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs

    Sang Hee Park1, Taylor Schwartz2, Xue Han1, Scott Robinson2, Sumie Kakehi1, Keith Wittstock1, Kris Norris2, Anne Murunga2, Alison Silverstein2 and Jeffrey Sparks3, 1Bristol Myers Squibb, Princeton, NJ, 2Avalere Health, Washington, DC, 3Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Recent exploratory clinical trial and retrospective studies1 suggest that patients with seropositive RA (rheumatoid factor [RF]+ and/or anti-cyclic citrullinated peptide [anti-CCP]+) treated with abatacept…
  • Abstract Number: 0568 • ACR Convergence 2021

    Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)

    Amy Joseph1, Jodi Yanagida1, Xinliang Huang1, Prabha Ranganathan1, Melissa Laurie2, Hong Xian1 and Seth Eisen1, 1VA St. Louis Health Care System, St. Louis, MO, 2Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers…
  • Abstract Number: 1230 • ACR Convergence 2021

    Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study

    Andrea Rubbert-Roth1, Jeffrey Sparks2, Arnaud Constantin3, Ricardo Xavier4, Yanna Song5, Jessica Suboticki5 and Roy Fleischmann6, 1Kantonspital St Gallen, St.Gallen, Switzerland, 2Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 3Toulouse University Hospital, Toulouse Cedex 9, France, 4Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 5AbbVie Inc., North Chicago, IL, 6University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: In patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority…
  • Abstract Number: 1517 • ACR Convergence 2021

    Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade

    Sophia Weinmann1, Amanda Eudy2 and David Pisetsky1, 1Duke University Medical Center, Durham, NC, 2Duke University, Durham, NC

    Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
  • Abstract Number: 1648 • ACR Convergence 2021

    Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis

    Dylan Bergstedt1, Ryan Peterson2, Marie Feser1, LauraKay Moss1, Geoffrey Thiele3, Ted Mikuls3, Jess Edison4, V. Michael Holers1 and Kevin Deane5, 1University of Colorado Denver, Aurora, CO, 2Colorado School of Public Health, Aurora, CO, 3University of Nebraska Medical Center, Omaha, NE, 4Walter Reed National Military Medical Center, Bethesda, MD, 5University of Colorado Denver, Denver, CO

    Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
  • Abstract Number: 1698 • ACR Convergence 2020

    Polyarthritis Workup in Primary Care Setting : How Are We Doing?

    Ruhani Desai1, Cassandra Calabrese2, Neel Patel3 and Jessica Donato4, 1Cleveland Clinic Foundation, DeLand, FL, 2Cleveland Clinic, Cleveland, OH, 3Case Western Reserve University, Cleveland, OH, 4Cleveland Clinic Foundation, Cleveland

    Background/Purpose: Joint pain is a common presenting complaint in Primary Care with around 54.4 million adults diagnosed with some form of arthritis per 2013 CDC survey. Polyarthritis…
  • Abstract Number: 1720 • ACR Convergence 2020

    Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals

    Hyoun-Ah Kim1, Ryan Peterson2, Gary Firestein3, David Boyle4, Jane Buckner5, Sylvia Posso6, Eddie James5, William Robinson7, Jaron Arbet2, LauraKay Moss8, Roger Gilmore8, Lindsay Hartje8, Saman Barzideh8, Jennifer Seifert9, Navin Rao10, Frédéric Baribaud11, Sunil Nagpal12, Alyssa Johnson13, V Michael Holers14 and Kevin D. Deane15, 1University of Colorado Anschutz Medical Campus and Ajou University School of Medicine, Aurora, CO, 2Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 3University of California, San Diego, La Jolla, CA, 4UC San Diego, San Diego, CA, 5Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 6Benaroya Research Institute at Virginia Mason, Seattle, WA, 7Stanford University, Palo Alto, CA, 8University of Colorado Anschutz Medical Campus, Aurora, CO, 9Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, 10Janssen R&D, Spring House, PA, 11Janssen Research & Development, LLC, Spring House, PA, 12Janssen Reserach and Development, Spring House, PA, 13Janssen Research and Development, Spring House, PA, 14Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, 152 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado

    Background/Purpose: Individuals at high-risk for future rheumatoid arthritis (RA) may be identified by screening for circulating RA-related autoantibodies including antibodies to citrullinated protein antigens (ACPA).…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies